Bio Rad Labs Inc Stock Price, News & Analysis

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) will report its financial results for Q1 2022 on April 28, 2022, after the market closes. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET). The company, a leader in life science research and clinical diagnostics, had revenues of $2.9 billion in 2021 and has been operational since 1952, serving a global customer base focused on advancing healthcare.

Bio-Rad Laboratories, Inc. (NYSE: BIO) has successfully closed an underwritten public offering of $1.2 billion in aggregate principal amount of notes. The offering consists of $400 million due in 2027 and $800 million due in 2032, with interest rates of 3.300% and 3.700%, respectively. The proceeds will be used for general corporate purposes, including working capital and potential acquisitions. Major banks such as Citigroup, Goldman Sachs, and J.P. Morgan managed the offering. Bio-Rad reported revenues of $2.9 billion in 2021.

Bio-Rad Laboratories, Inc. (NYSE: BIO) is hosting an investor day in New York City, highlighting its growth strategy and financial targets. The company aims for a 9% core revenue CAGR from 2021 to 2025 and a 28% adjusted EBITDA margin by 2025. Bio-Rad emphasizes portfolio transformation and expansion in the biopharma sector. The Life Science Research and Clinical Diagnostics segments are expected to drive growth through advanced products and solutions. Bio-Rad has consistently exceeded its previous financial targets, setting a positive outlook for future performance.

Bio-Rad Laboratories reported Q4 2021 net sales of $732.8 million, down 7.2% year-over-year, with a gross margin of 54.7%. The Life Science segment saw a 23.8% sales decline primarily due to reduced COVID-19 demand, while Clinical Diagnostics rose by 12.6%. The company experienced a net loss of $1,573.7 million or $52.59 per diluted share, impacted by equity securities valuation changes. For full-year 2021, net sales increased 14.8% to $2.92 billion with a net income of $4.24 billion.

Bio-Rad Laboratories (NYSE: BIO, BIOb) has announced an in-person investor day in New York City on February 25, 2022, starting at 10:30 a.m. EST. The event will include presentations from CEO Norman Schwartz and the executive leadership team, followed by a Q&A session. A live webcast will be available, with registration required for attendance. A replay and the presentation slides will be accessible on Bio-Rad's website for a year. The company, a leader in life science research and clinical diagnostics, reported revenues exceeding $2.5 billion in 2020.

Bio-Rad Laboratories, Inc. (NYSE: BIO) will report its financial results for Q4 and full year 2021 on February 10, 2022, after market close. The company will host a conference call at 3 PM PT (6 PM ET) to discuss the results. Investors can listen by calling in or via a live webcast. Bio-Rad is a leader in life science research and clinical diagnostics, with 2020 revenues exceeding $2.5 billion.

Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, will participate in a virtual Fireside Chat at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 1:30 PM PST. Key executives, including President and CEO Norman Schwartz, will present insights during the event. The live webcast can be accessed via the Bio-Rad Investor Relations website. Founded in 1952 and based in Hercules, California, Bio-Rad reported revenues exceeding $2.5 billion in 2020, serving a diverse clientele in various markets.

Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) has appointed Simon May as Executive Vice President and President of the Life Science Group, effective January 4, 2022. He takes over from Annette Tumolo, who will retire at that time. Dr. May previously led the Digital Biology Group, overseeing significant growth and acquisitions. His extensive experience in commercial operations makes him well-suited for this role. Bio-Rad, based in Hercules, California, achieved revenues exceeding $2.5 billion in 2020.

BioGX announced that its SARS-CoV-2 diagnostic portfolio can detect the Omicron variant (B.1.1.529). The surveillance program includes in-silico analyses confirming detection across all variants of interest. BioGX's COVID-19 RT-PCR tests are compatible with several real-time PCR platforms, notably the Xfree COVID-19 Direct RT-PCR, which is FDA authorized for multiple specimen types. This test offers extraction-free options, enhancing workflow efficiency. BioGX operates under ISO 13485 standards, providing over 60 multiplex real-time PCR products worldwide.